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Activation of liver X receptors (LXRs) with synthetic agonists promotes
reverse cholesterol transport and protects against atherosclerosis
in mouse models. Most synthetic LXR agonists also cause marked
hypertriglyceridemia by inducing the expression of sterol regulatory
element-binding protein (SREBP)1c and downstream genes that drive
fatty acid biosynthesis. Recent studies demonstrated that desmosterol,
an intermediate in the cholesterol biosynthetic pathway that sup-
presses SREBP processing by binding to SCAP, also binds and activates
LXRs and is the most abundant LXR ligand in macrophage foam cells.
Here we explore the potential of increasing endogenous desmosterol
production ormimicking its activity as ameans of inducing LXR activity
while simultaneously suppressing SREBP1c-induced hypertriglyceride-
mia. Unexpectedly, while desmosterol strongly activated LXR target
genes and suppressed SREBP pathways in mouse and human macro-
phages, it had almost no activity in mouse or human hepatocytes in
vitro. We further demonstrate that sterol-based selective modulators
of LXRs have biochemical and transcriptional properties predicted of
desmosterol mimetics and selectively regulate LXR function in macro-
phages in vitro and in vivo. These studies thereby reveal cell-specific
discrimination of endogenous and synthetic regulators of LXRs and
SREBPs, providing amolecular basis for dissociation of LXR functions in
macrophages from those in the liver that lead to hypertriglyceridemia.
macrophage | LXR | hepatocyte | cholesterol | SREBP
Although improvements in the prevention and treatment ofcardiovascular disease (CVD) over the last decade have
contributed to a significant reduction in the burden of CVD, it still
accounts for nearly a third of all deaths in the United States and
worldwide each year (1). In fact, more people die each year sec-
ondary to CVD than any other cause, with coronary heart disease
and stroke representing the majority of cases (2). Increased apoli-
poprotein B-100–associated lipid species, namely LDL cholesterol
(LDL-C), remains one of the best-appreciated risk factors for
atherosclerotic heart disease. Accordingly, reduction of LDL-C
through the use of statins or recently developed antibodies di-
rected against proprotein convertase subtilisin/kexin type 9 repre-
sents one of the mainstays of preventive therapy (3, 4). However,
myocardial infarction and stroke still occur in a subset of indi-
viduals despite cholesterol lowering, and therapies directed at
additional targets are of potential clinical benefit.
Macrophages are key cellular players in the initiation and pro-
gression of atherosclerosis through their roles in uptake of modified
lipoproteins in the artery wall, production of inflammatory mediators,
and secretion of metalloproteases that contribute to plaque instability
(5–8). A subset of macrophages within atherosclerotic lesions are
characterized by massive accumulation of cholesterol esters in lipid
droplets, resulting in a “foam cell” phenotype indicative of a failure
of normal cholesterol homeostasis. Given their central role in in-
tegrating both cholesterol homeostasis and inflammatory signaling
in macrophages, the liver X receptors (LXRs) represent logical
targets for pharmacologic intervention in atherosclerosis (9–11).
LXR activation is known to promote cholesterol efflux in macro-
phages by activation of ATP-binding cassette transporter A1 and
G1 (ABCA1/ABCG1) (12, 13) while also repressing the proin-
flammatory products of NF-κB signaling (14). Stimulation of cho-
lesterol efflux in macrophages and other cell types contributes to
overall functions of LXRs in mediating reverse cholesterol transport
from peripheral cells to the liver for biliary secretion (15, 16).
Consistent with these homeostatic functions, deletion of LXRs
either at the whole-body level or within the hematopoietic
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compartment results in accelerated atherosclerosis in mouse
models (17, 18). Conversely, administration of potent synthetic
LXR agonists, such as GW3965, inhibits the development of
atherosclerosis in these models (19–21). However, most synthetic
agonists of LXR have also been found to strongly activate sterol
regulatory element-binding protein (SREBP)1c and downstream
genes involved in fatty acid biosynthesis, including fatty acid
synthase (FAS), that subsequently lead to increased serum
cholesterol and triglyceride levels (22, 23). Thus, while activating
LXR has positive effects in the prevention of atherosclerosis in
terms of enhancing reverse cholesterol transport and suppression
of proinflammatory pathways, the negative aspect of hyper-
triglyceridemia and fatty liver—a product of SREBP activation—
has prevented synthetic LXR agonists from being clinically
useful therapeutics. Empiric efforts to develop “dissociated”
LXR agonists that retain the ability to activate LXRs but do not
induce hypertriglyceridemia have been partially successful (24–
27), but underlying mechanisms are poorly understood.
LXR activity is normally induced under conditions of choles-
terol excess in a manner that is reciprocal to coordinate inhibi-
tion of the processing of the SREBP transcription factors. LXRs
do not sense cholesterol directly but are instead positively reg-
ulated by oxysterols and intermediates in the cholesterol bio-
synthetic pathway (28–30). In contrast to most synthetic LXR
agonists, natural LXR agonists also suppress processing of the
SREBP proteins (31). In the case of oxysterols, such as 25-
hydroxycholesterol, inhibition is mediated through interactions
with the insulin-induced gene (INSIG) proteins that prevent
trafficking of SREBPs to the Golgi for proteolytic activation
(32). The cholesterol biosynthetic intermediate desmosterol was
first noted to be an endogenous LXR-activating ligand in studies
of plant sterols and sterol intermediates in the cholesterol bio-
synthetic pathway (30). In contrast to oxysterols, desmosterol
most likely suppresses SREBP processing by interacting with
SREBP cleavage-activating protein (SCAP) to retain the SREBPs
in the endoplasmic reticulum (31).
In a lipidomic analysis of murine macrophage foam cells and
human atherosclerotic plaques, desmosterol was found to be the
most abundant endogenous LXR activator (33). The accumulation
of desmosterol in macrophage foam cells was correlated with
down-regulation ofDhcr24, which encodes the 24-dehydroxycholesterol
reductase enzyme that converts desmosterol to cholesterol (Fig.
1A). Notably, treatment of macrophages with increasing con-
centrations of desmosterol led to coordinate increases in LXR-
dependent pathways and suppression of SREPB pathways. As a
consequence, genes involved in cholesterol efflux were induced,
while genes involved in cholesterol and fatty acid synthesis were
down-regulated (33). These findings confirmed the prediction
that desmosterol could balance lipid homeostasis via reciprocal
actions on LXR and SREBP activities (30).
These observations raised the questions of whether the des-
mosterol pathway operates in other cell types and whether it
would be possible to activate this pathway, or mimic it, as a
therapeutic strategy. Studies in mouse macrophages pointed to
down-regulation of Dhcr24 as being the key event leading to
accumulation of desmosterol (33). One straightforward strat-
egy would thus be to inhibit 24-dehydrocholesterol reductase
(DHCR24) activity. Remarkably, this was first achieved more
than 50 y ago following the identification of triparanol (also
known as mer-29) as a potent inhibitor of DHCR24. Adminis-
tration of triparanol to hypercholesterolemic human subjects led
to marked reductions in serum cholesterol and corresponding
rises in circulating desmosterol (34, 35). However, triparanol was
rapidly withdrawn from the market after reports of severe cataracts
and alopecia (36–38), and there is no evidence of whether there
was an impact on the development of cardiovascular diseases.
While there are dermatologic manifestations of desmosterolosis, it
is unknown if the extent of alopecia or development of cataracts is
specifically related to increased circulating desmosterol or poten-
tially an off-target effect of triparanol (39).
Here we investigate the potential to modulate and mimic the
desmosterol pathway in vivo and in vitro as a means of co-
ordinately regulating the LXR and SREBP pathways. To modu-
late the desmosterol pathway in vivo, we developed potent and
specific antisense oligonucleotides (ASOs) that reduce Dhcr24
expression in the liver by more than 80%. Unexpectedly, while this
treatment resulted in significant increases in endogenous des-
mosterol, no significant changes in LXR or SREBP target genes
were observed in the liver. To mimic the desmosterol pathway, we
demonstrate that the previously reported selective LXR modula-
tors DMHCA (27) and MePipHCA (40) have properties of syn-
thetic desmosterol mimetics. While desmosterol, DMHCA, and
MePipHCA coordinately regulate the LXR and SREBP pathways
in primary mouse and human macrophages, they exhibit very little
effect on gene expression in primary mouse and human hepato-
cytes. The differential effects of DMHCA and MePipHCA on
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Fig. 1. Effect of 24-dehydrocholesterol reductase-specific antisense oligo-
nucleotide treatment in mice. (A) Catalysis of the final step in cholesterol
biosynthesis by Dhcr24. (B) Effect of treatment of mouse thioglycollate-
elicited macrophages with four separate ASOs to Dhcr24 (ION-599805,
ION-599830, ION-599832, and ION-599847, hereafter indicated as 805, 830,
832, and 847, respectively) or an ASO directed at Mmp9 (MMP9 ASO), as
assessed by RT-qPCR (*P < 0.0001 vs. SCR). (C) Gene expression levels of the
indicated genes in mouse liver after treatment with ASO (**P < 0.001). (D)
Western immunoblot analysis of Dhcr24 and actin in liver protein extracts in
mice treated with the indicated Dhcr24-specific ASOs. (E) Plasma and liver
desmosterol concentrations as measured by LC-MS in mice treated with
Dhcr24-specific compared with SCR ASOs (**P < 0.01, ***P < 0.001). Error
bars represent standard errors.
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LXR and SREBP target genes in macrophages and hepatocytes
are also observed in vivo. Remarkably, LXR target genes are acti-
vated in Kupffer cells in response to DMHCA, in contrast to liver as a
whole. In concert, these findings suggest a molecular basis for
dissociation of LXR functions in macrophages and hepatocytes
that would enable retention of antiatherogenic properties with-
out promoting hypertriglyceridemia.
Results
Blockade of DHCR24 Using Gene-Specific ASOs Leads to Increased
Endogenous Desmosterol Without Potentiating LXR-Mediated Target
Genes. To modulate the endogenous desmosterol pathway for
coordinate regulation of LXR and SREBP target genes in vivo, we
developed ASOs specific to DHCR24. Based on the effects of
inhibition of DHCR24 by triparanol and genetic deficiency of
Dhcr24, we hypothesized that reduction of Dhcr24 expression
would lead to increased desmosterol levels and corresponding
changes in LXR- and SREBP-dependent gene expression (Fig.
1A). Out of more than 50 potential Dhcr24-specific ASOs de-
veloped and initially assayed, we tested four of the most active
ASOs in plated thioglycollate-elicited macrophages (TGEMs)
(Fig. 1B). After 48 h of exposure to ASO,Dhcr24 gene expression as
assessed through quantitative real-time PCR (qRT-PCR) was less
than a quarter of scramble (SCR) control with four separate
Dhcr24-specific ASOs (ION-599805, ION-599830, ION-599832,
and ION-599847, hereafter referred to as 805, 830, 832, and
847, respectively). Dhcr24 gene expression was also unchanged by
a negative control MMP9 ASO compared with the SCR-treated
cells. We then aimed to use these ASOs to reduce Dhcr24 expres-
sion in C57BL/6 mice.
We delivered control (SCR) ASO and the DHCR24-specific
ASOs 805 and ION-599873 (referred to as 873) to six mice per
group via biweekly i.p. injections over a 3-wk period (Fig. S1A).
The treatment regimen was well-tolerated in all study groups,
with expected weight gain and no difference in body weights
at the termination of the study (Fig. S1B). Following 3 wk of
treatment, hepatic expression of Dhcr24 was markedly reduced
in both cohorts of Dhcr24 ASO-treated animals compared with
SCR control (15 and 25% vs. SCR control for 805 and 873, re-
spectively, P < 0.001) (Fig. 1C). This was mirrored by a sub-
stantial reduction in DHCR24 gene product as examined by
Western immunoblot analysis of liver extract (Fig. 1D). Con-
comitant with this reduction of Dhcr24 gene expression and
protein, circulating plasma desmosterol increased by 10-fold af-
ter treatment with Dhcr24 ASO (0.38 ± 0.04, 3.97 ± 0.65, and
2.27 ± 0.50 μM for SCR, 805, and 873, respectively) as measured
by liquid chromatography-mass spectrometry (LC-MS) (Fig. 1E).
In addition, hepatic desmosterol levels increased after Dhcr24
ASO treatment (1.87 ± 0.53, 12.50 ± 2.01, and 16.23 ± 4.34 ng/mg
for SCR, 805, and 873, respectively), attributable mainly to increases
in free rather than esterified desmosterol (Fig. 1E). Surprisingly,
despite these increases in circulating and hepatic desmosterol,
there were no observed alterations in the expression of the key
hepatic LXR target genes ATP-binding cassette transporter
subfamily A, member 1 (Abac1), ATP-binding cassette transporter
subfamily G, member 5 (Abcg5), or ATP-binding cassette trans-
porter subfamily G, member 8 (Abcg8) inDhcr24ASO-treated animals
versus SCR control (Fig. 1C). Nor were there differences in the
hepatic expression of SREBP target genes (Fig. 1C).
In a second experimental paradigm, we performed 1 wk of s.c.
ASO treatment in C57BL/6 mice that received thioglycollate 4 d
before study end. Both liver and TGEMs showed a reduction in
Dhcr24 gene expression, although macrophages responded less
robustly than liver (95 and 73% reduction in the liver and
macrophages of Dhcr24 ASO- vs. SCR control-treated animals,
respectively) (Fig. S1C). As in the case of liver, the major LXR
target genes Abca1 and Abcg1 were not significantly modulated
(P value is not significant for both, Dhcr24 ASO vs. SCR ASO)
despite increased desmosterol concentrations in plasma, liver, and
macrophages (Fig. S1D). Taken together, these data show that while
Dhcr24-specific ASOs reduced hepatic and macrophage expression
ofDhcr24mRNA and protein, leading to increased levels of cellular
and circulating desmosterol, they did not lead to activation of LXR
target genes or suppression of SREBP target genes.
Cell Type-Specific Effect of Desmosterol in Macrophages Compared
with Hepatocytes. The lack of an effect of knockdown of Dhcr24
in the liver on LXR or SREBP target genes despite a significant
increase in hepatic desmosterol raised the questions of whether
desmosterol reached sufficient intracellular concentrations to be
active and/or whether the desmosterol pathway is utilized in the
liver. To directly compare responses of macrophages and hepa-
tocytes to desmosterol, we evaluated the expression of Dhcr24
and Abca1 in plated TGEMs and DHCR24 and ABCA1 in
HepG2 cells treated with increasing concentrations of desmos-
terol and the synthetic LXR ligand T0901317 (Fig. 2A). Whereas
treatment with T0901317 resulted in an increase of Abca1 ex-
pression in TGEMs (19.05 ± 3.86, P < 0.01 for 1 μM T0901317
relative to vehicle) and ABCA1 expression in HepG2 cells
(1.80 ± 0.30, P < 0.01 for 1 μMT0901317 relative to vehicle), this
LXR target gene was up-regulated only in TGEMs (8.51 ± 1.40,
P < 0.01 relative to vehicle) but not HepG2 cells after treatment
with 10 μM desmosterol. In addition, while there was no effect of
T0901317 on the suppression of the SREBP target gene Dhcr24
in either cell type, treatment with 10 μM desmosterol resulted in
a marked down-regulation of Dhcr24 (0.19 ± 0.08, P < 0.01 rela-
tive to vehicle) solely in TGEMs (Fig. 2A).
To further explore the specific LXR- and SREBP-dependent
gene responses to desmosterol, we performed qRT-PCR analysis
in primary macrophages and primary hepatocytes from both mice
and humans (Fig. 2 B and C). Treatment of TGEMs with 10 μM
desmosterol resulted in an increase in the LXR-responsive gene
Abca1 (8.06 ± 1.80, P < 0.05 relative to vehicle) and a decrease in
Dhcr24 (0.19 ± 0.04, P < 0.05 relative to vehicle) without subsequent
activation of the SREBP-responsive gene fatty acid synthase (Fasn),
whereas it had no effect in primary mouse hepatocytes (Fig. 2B). In
contrast, treatment of cells with the synthetic selective LXR ligand
GW3965 resulted in increased levels of Abca1 (22.77 ± 4.62, P <
0.05 relative to vehicle) and Fasn (7.13 ± 1.64, P < 0.05 relative to
vehicle) mRNA in both macrophages and hepatocytes (5.58 ±
1.28, P < 0.05 and 3.64 ± 0.34, P < 0.05 for Abca1 and Fasn, re-
spectively) (Fig. 2B). The LXR and SREBP target gene expression
changes induced by desmosterol and GW3965 in mouse macrophages
and hepatocytes were fully recapitulated in human monocyte-derived
macrophages (HMDMs) and primary hepatocytes (Fig. 2C).
These data suggest that while desmosterol effectively leads to a
dose-dependent increase in LXR target genes without inducing
SREBP target genes, as is seen for synthetic selective LXR ligands
in both human and mouse macrophages, these effects are largely
absent in hepatocytes.
To examine possible mechanisms, we performed lipidomic analy-
ses of TGEMs and primary hepatocytes from mice. Desmosterol was
by far the most abundant LXR ligand present in both cell types in an
inactivated/unstimulated state (Fig. 3A). In contrast, the oxysterol
ligands 25-hydroxycholesterol and 27-hydroxycholesterol, implicated
in regulating LXR activity based on genetic deletion of the genes
encoding 24-, 25-, and 27-cholesterolhydroxylases (41), were almost
exclusively found in hepatocytes, while 24(S)-hydroxycholesterol was
not detected in either cell type (Fig. 3B). Evaluation of the extent to
which exogenous desmosterol (10 μM) was taken up by macrophages
and hepatocytes indicated a time-dependent accumulation in both
cell types, with ∼30% greater uptake occurring in macrophages after
4 h (Fig. 3 C and D). Following 1 h of desmosterol loading (10 μM),
TGEMs and hepatocytes were washed and fresh media lacking
desmosterol were added. Cell-associated desmosterol remained
constant over the next 4 h in macrophages but dropped significantly
E4682 | www.pnas.org/cgi/doi/10.1073/pnas.1714518115 Muse et al.
by 1 h in hepatocytes (Fig. 3 E and F). Collectively, these changes
suggest differences in metabolism and compartmentalization of
desmosterol and oxysterols in macrophages and hepatocytes
that are consistent with the observed selectivity of exogenous
desmosterol in regulating LXR- and SREBP-dependent gene
expression in macrophages.
Synthetic Desmosterol Mimetics Exhibit a Cell Type-Specific LXR
Activation Profile Similar to Desmosterol. Appreciating the differential
LXR- and SREBP target gene response in macrophages and hepa-
tocytes of desmosterol compared with conventional LXR ligands
(e.g., GW3965, T0901317), we sought synthetic compounds that
might represent desmosterol mimetics. Such molecules by definition
would have the functional properties of coordinately activating LXR
target genes and suppressing SREBP1 and SREBP2 target genes.
While the chemical structures of GW3965 and T0901317 are vastly
dissimilar to desmosterol (Fig. 4A), DMHCA, a previously reported
synthetic dissociated LXR agonist with antiatherosclerotic potential,
retains much of the same desmosterol chemical backbone (24, 26,
27). In TGEMs, DMHCA not only activates LXR target genes such
as Abca1 and fails to induce Fasn expression, as previously reported,
but also strongly represses the SREBP target gene Dhcr24 (Fig. 4B).
This activity profile is thus consistent with that of a desmosterol
mimetic. In addition, we evaluated recently developed derivatives of
DMHCA, exemplified by MePipHCA, which we reported as a dis-
sociated LXR agonist that inhibits inflammation in models of trau-
matic brain injury and inflammatory bowel disease (40). Similar to
DMHCA, MePipHCA not only activated the LXR target genes in
macrophages but also strongly suppressed Dhcr24 expression (Fig.
4C). We also observed that, in contrast to T0901317, DMHCA and
MePipHCA did not cause lipid accumulation in HepG2 cells after
72-h treatment (Fig. 4D), consistent with a lack of an effect of
DMHCA and MePipHCA on SREBP1c expression and lipid bio-
genesis in these cells.
Whole-Transcriptome Assessment of Desmosterol Mimetics. In view
of the cell type-specific characteristics of desmosterol signaling,
the similarities shared with DMHCA, especially in terms of the
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Fig. 2. LXR- and SREBP-mediated gene expression profiles in mouse and
human macrophages and hepatocytes. (A) Dose-dependent modulation of
Dhcr24 and ABCA1 in plated TGEMs and HepG2 cells by desmosterol and
T0901317 (*P < 0.01). (B) In mouse TGEMs, desmosterol (Des; 10 μM) induces
expression of Abca1 while suppressing Dhcr24 without affecting Fasn,
whereas the synthetic LXR ligand GW3965 (GW; 1 μM) induces the expression
of Fasn. In primary mouse hepatocytes, desmosterol fails to illicit changes in
Abca1 and Dhcr24 while GW3965 retains its ability to activate LXR and SREBP
(*P < 0.05 vs. Veh; •P < 0.05 vs. desmosterol). (C) The action of desmosterol
(10 μM) and GW3965 (1 μM) on ABCA1, DHCR24, and FASN in cultured human
monocyte-derived macrophages and human primary hepatocytes recapitulates
the transcriptional activities observed in mouse TGEMs and hepatocytes (*P <
0.05 vs. Veh; •P < 0.05 vs. desmosterol). HPRT, hypoxanthine-guanine phos-
phoribosyltransferase. Error bars represent standard errors.
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dissociation of LXR- and SREBP-pathway regulation, and the
promise of the structurally related mimetic MePipHCA, we
conducted an unbiased, whole-transcriptome comparison of
these ligands with the conventional LXR ligands GW3965 and
T0901317 using RNA-sequencing (RNA-seq) analysis. We began
by treating plated TGEMs and mouse primary hepatocytes with
desmosterol (10 μM), DMHCA (1 μM), MePipHCA (1 μM),
GW3965 (1 μM), and T0901317 (1 μM). Representative scatter
plots show that while treatment with desmosterol, DMHCA, or
T0901317 leads to a robust LXR response in TGEMs, the overall
LXR response is absent in hepatocytes except after treatment
with T0901317 (Fig. 5A). Heat maps of individual genes from key
LXR and SREBP pathways illustrate that while all compounds
tested in TGEMs induce Abca1 expression (LXR-responsive
gene), desmosterol, DMHCA, and MePipHCA repress SREBP-
responsive genes (Dhcr24, Hmgcr, and Ldlr) while GW3965 and
T0901317 activate Fasn and Srebf1 (Fig. 5B). In mouse primary
hepatocytes, only GW3965 and T0901317 retain the expected
LXR activities and activate SREBP1c target genes such as Fasn.
Gene ontology (GO) term analysis of specific up- and down-
regulated gene pathways reinforced the LXR-activating effect of
all compounds in TGEMs and the combined LXR- and SREBP1c-
activating effect of GW3965 and T0901317 in both TGEMs and
hepatocytes (Fig. 5C). Notably, the SREBP-mediated pathways
noted by the GO terms “cholesterol metabolic process” and “sterol
biosynthetic process” are markedly suppressed by desmosterol,
DMHCA, and MePipHCA in macrophages (Fig. 5C). In prin-
cipal component analysis (PCA) performed on the differentially
expressed genes (up and down) in both TGEMs (Left) and primary
hepatocytes (Right), the conventional ligands GW3965 and T0901317
cluster tightly together, as do desmosterol and DMHCA, with
MePipHCA assorting itself distinctly along the first two eigenvec-
tors (Fig. 5D). The divergence of MePipHCA for up-regulated
genes is partly driven by its activation of several genes that have
functional annotations associated with the “response to unfolded
protein” pathway in GO term analysis, including Atf4, Chac1, Ddit3,
and Chop (Fig. S2A). Of note, this pathway is also activated by 25-
hydroxycholesterol in macrophages (42).
We observed similar differences in the transcriptional re-
sponses of macrophages and hepatocytes in our unbiased, whole-
transcriptome RNA-seq analysis of human cells. First, we com-
pared the global response of up- and down-regulated genes in
response to these ligands in both HMDMs and human primary
hepatocytes (Fig. 6A). Notably, and similar to our studies in
mouse cells, desmosterol and DMHCA activated LXR target
genes and blunted SREBP1 and SREBP2 target genes in
HMDMs but exhibited minimal effects on these genes in primary
hepatocytes. In contrast, T0901317 activated LXR and SREBP1
target genes in both cell types. The most significant transcrip-
tional pathways up- and down-regulated by these treatments in
HMDMs and human primary hepatocytes are relatively un-
changed from mouse, with the coordinated activation of reverse
cholesterol transport and suppression of cholesterol and tri-
glyceride biosynthetic pathways observed in macrophages (Fig.
6B). This pathway analysis is supported on the individual gene
level (Fig. 6C). In addition, HMDMs from five individual patients
with varying degrees of coronary atherosclerosis and comorbid
chronic diseases were treated with desmosterol, DMHCA, and
T0901317. While the range of transcriptional responses to these
ligands likely highlights the influence of natural genetic variation,
all HMDMs showed robust increases in LXR-mediated genes
(ABCA1, ABCG1) when treated with desmosterol, DMHCA,
and T0901317. T0901317 activated SREBP target genes (SCD,
FASN), while these genes were suppressed or unchanged in re-
sponse to desmosterol or DMHCA, respectively. Most apparent
here is the global similarity of DMHCA to the natural oxysterol
desmosterol in regard to LXR and SREBP transcriptional control,
and their differences with the conventional LXR agonist T0901317
(Fig. 6C). While desmosterol, DMHCA, and MePipHCA activate
LXR-mediated pathways and suppress SREBP-mediated pathways
in macrophages of mice and humans, this response is absent or
blunted in primary hepatocytes. Conversely, GW3965 and T0901317
remain potent activators of LXR-pathway genes in both cell types
while activating SREBP-responsive genes in tandem. MePipHCA
also activated a subset of genes associated with the unfolded protein
response, as observed in mouse macrophages (Fig. S2B).
While the vast majority of genes that were up- and down-
regulated by desmosterol, DMHCA, and T0901317 were shared
in mouse and human macrophages, we also noted certain genes
that were differentially regulated (Fig. 6D). While the roles of
many of these genes in lipid homeostasis and regulation of in-
flammation remain unappreciated, we did observe differences in
key genes such as the nuclear receptor LXRα (NR1H3) and retinoic
acid receptor (RARA), both differentially induced in HMDMs, and
several regulators of lipid metabolism such as fatty acid desaturase
(FADS1), 7-dehydrocholesterol reductase (DHCR7), and farnesyl-
diphosphate farnyltransferase (FDFT1), all suppressed in HMDMs
compared with mouse TGEMs.
The Macrophage-Specific Induction of LXR-Responsive Genes Without
Potentiation of SREBP Pathways with Synthetic Desmosterol Mimetics
Is Recapitulated in Vivo.We then sought to examine if the cell type-
specific effects observed in plated macrophages and hepatocytes in
response to desmosterol and desmosterol mimetics (DMHCA and
MePipHCA) were recapitulated in an in vivo model. We treated
mice with thioglycollate by i.p. injection 4 d before treatment with
compounds to elicit macrophage accumulation in the peritoneum.
DMHCA, MePipHCA, and T0901317 (50 mg/kg) were then given
by i.p. injection 6 and 16 h before peritoneal macrophages, and
whole liver was isolated and prepared for gene expression analysis.
Gene expression of the LXR-responsive gene Abca1 was robustly
induced in peritoneal macrophages at 6 h by T0901317, DMHCA,
and MePipHCA, whereas only T0901317 induced a coordinate
response in Abcg5 in the liver (Fig. 7A). The LXR-activating effect
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for DMHCA and MePipHCA was attenuated at 16 h in macro-
phages, though remained strong for T0901317 in both tissues.
Mirroring what we had observed in in vitro studies, treatment with
T0901317 led to the induction of SREBP-responsive genes, illus-
trated here by Fasn, in both macrophages and liver, while DMHCA
and MePipHCA did not induce Fasn in either tissue.
Although responses to DMHCA and MePipHCA were minimal
or absent in intact liver, it was of interest to determine whether
Kupffer cells, the resident macrophage population of the liver,
exhibited similar responses to those observed in elicited peritoneal
macrophages. To address this question, we treated mice with ve-
hicle, DMHCA, or T0901317 by i.p. injection, and 12 h following
injection Kupffer cells were purified by fluorescence-activated cell
sorting with target cells identified by CD45+F4/80+CD11bintTim4+
CD146−CD31− (Fig. S3). As in the case of peritoneal macrophages,
DMHCA was shown to selectively activate LXR-responsive genes
in Kupffer cells (Abca1) but not whole liver (Abcg5) (Fig. 7B).
DMHCA had no effect on the SREBP1-responsive gene Fas in
either Kupffer cells or intact liver compared with T0901317, and
modestly repressed Hmgcr in Kupffer cells (Fig. S3). Of note,
DMHCA activated Scd2 in Kupffer cells but not intact liver, con-
sistent with the ability of Scd2 to be activated independently by the
LXR and SREBP1 pathways (33). These results indicate that these
sterol-based synthetic LXR agonists (DMHCA and MePipHCA)
appear to act preferentially in macrophages (and Kupffer cells)
compared with hepatocytes in vivo and, unlike T0901317, without
potentiating SREBP1-responsive genes at the level of intact liver.
Discussion
Despite their key roles at the intersection of lipid metabolism
and inflammation, the promise of LXRs as pharmacologic tar-
gets for the prevention and treatment of atherosclerotic heart
disease has been limited by the difficulty of decoupling beneficial
effects from activation of SREBP1-dependent pathways. Devel-
opment of selective LXR modulators has been challenging in
part because there are few evident rationale approaches for
achieving this goal. A leading strategy has been to synthesize
molecules that preferentially activate LXRβ, based on evidence
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for a dominant role of LXRα in driving SREBP1c expression and
fatty acid biosynthesis in mouse liver (9, 19, 42, 43). However, a
recent evaluation of a prototypic LXRβ-selective synthetic ligand
demonstrated that in addition to induction of LXR target genes
in human blood cells and inhibition of atherosclerosis in mouse
models, it retained the ability to increase circulating triglyceride
levels and hepatic triglycerides in human subjects (44).
Here we have explored an alternative strategy that is based on
the observation that most or all physiologic LXR agonists are
also inhibitors of SREBP processing, either by binding to INSIGs
(e.g., oxysterols) or SCAP (desmosterol). In contrast to synthetic
agonists that selectively target LXRs, such endogenous ligands
would be expected to activate genes involved in reduction of
cellular cholesterol but have an attenuated effect on fatty acid
biosynthesis due to inhibitory effects on processing of SREBP1c.
We thus sought to test the hypothesis that raising endogenous
levels of LXR agonists or mimicking their activity would have
these effects.
Our initial in vivo approach was to increase intracellular
concentrations of desmosterol by specifically reducing the ac-
tivity of DHCR24 using antisense oligonucleotide technology.
Unexpectedly, despite a marked elevation in hepatic and circu-
lating desmosterol levels after treatment with Dhcr24-specific
ASOs, we failed to observe concomitant activation of key LXR-
responsive genes in the liver or macrophages. One possible in-
terpretation of this result is that, while significantly elevated,
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desmosterol did not reach intracellular concentrations required
to activate LXRs. This hypothesis was supported by our obser-
vation that 10 μM desmosterol significantly elevated LXR target
genes in TGEMs but not 1 μM desmosterol (Fig. 2A). In addi-
tion, serum desmosterol levels of Dhcr24 ASO-treated mice were
less than 20% of those observed in human subjects treated with
triparanol or in the rare genetic disease of desmosterolosis (39,
45, 46). We conclude that raising endogenous desmosterol levels
by reducing Dhcr24 expression using ASOs is unlikely to be an
effective strategy for activation of LXRs in vivo.
Given the inability to modulate the LXR axis by increasing
endogenous desmosterol concentrations with Dhcr24 ASO, we
sought to specifically assess the desmosterol pathway in hepa-
tocytes. Unexpectedly, we observed that concentrations of des-
mosterol that effectively activated LXR-responsive genes and
suppressed SREBP-responsive genes in macrophages had little
or no effect on these genes in mouse and human hepatocytes.
Thus, these studies provide evidence for a cell-autonomous
mechanism enabling cell-specific discrimination of an endoge-
nous LXR ligand that confers selective activation of LXR target
genes in macrophages.
Based on these findings, we characterized DMHCA, an em-
pirically developed LXR agonist that exhibits antiatherosclerotic
activity without causing substantial hypertriglyceridemia in mice
(24). Importantly, unlike conventional LXR agonists such as GW3965
and T0901317, DMHCA is structurally related to desmosterol, raising
the possibility that it functions as a desmosterol mimetic. Consistent
with this possibility, DMHCA coordinately induced LXR target genes
and repressed both SREBP1 and SREBP2 target genes. We therefore
evaluated a series of derivatives capable of activating LXRs in
transient transfection assays, the most potent of which was MePipHCA.
This result provides evidence of the possibility of improving the
physicochemical properties of this class of compounds for pharma-
ceutical use.
Genome-wide comparisons of desmosterol, DMHCA,MePipHCA,
GW3965, and T0901317 in mouse and human macrophages
and hepatocytes strongly support the preferential activities of
desmosterol and desmosterol mimetics in macrophages and
demonstrate that they coordinately regulate the LXR and SREBP
pathways in these cells. Desmosterol, DMHCA, and MePipHCA
regulated a highly overlapping set of genes, with DMHCA and
MePipHCA exhibiting greater potency. Comparisons of the responses
of mouse and human macrophages also indicated a high degree of
similarity at the level of genes involved in cholesterol homeostasis.
A relatively small number of genes exhibited species-specific dif-
ferences in responses, primarily in human monocyte-derived macro-
phages, which are at this point of uncertain significance. There was
relatively little individual variation in responses of the core set of
LXR target genes involved in cholesterol homeostasis among the
small set of human monocyte-derived macrophages that were
evaluated. Importantly, the macrophage-selective activities of DMHCA
and MePipHCA were observed in vivo.
In addition to regulating the LXR/SREBP pathways, des-
mosterol was previously shown to inhibit inflammatory responses
in macrophages, consistent with the actions of other LXR ago-
nists (33). Although not evaluated for antiinflammatory effects
in these studies, we recently reported that MePipHCA signifi-
cantly reduced disease severity and inflammatory markers in
models of inflammatory bowel disease and traumatic brain injury
without causing lipid accumulation in the liver (40). A limitation
of the current synthetic desmosterol mimetics is a relatively poor
pharmacokinetic profile, requiring large doses for in vivo effi-
cacy. Therefore, it is likely that substantial additional effort will
be required to develop more drug-like molecules.
A major new and exciting question regards the basis for cell-
specific discrimination of desmosterol that confers preferential
activity in macrophages. It is unlikely to be simple conversion of
desmosterol to cholesterol or another LXR agonist, because sim-
ilar activities were observed for the synthetic agonists DMHCA
andMePipHCA. A cell-autonomous basis for this discrimination is
strongly supported by the finding that Kupffer cells in the liver
robustly respond to DMHCA, while surrounding hepatocytes do
not. Lipidomic studies indicate that desmosterol is by far the most
abundant LXR ligand in both macrophages and hepatocytes, while
25-hydroxycholesterol and 27-hydroxycholesterol are prefer-
entially found in hepatocytes. Notably, macrophages took up and
retained more exogenous desmosterol than hepatocytes. Collec-
tively, these findings suggest a hepatocyte-specific mechanism that
distinguishes between desmosterol/desmosterol mimetics and
oxysterols, given the genetic evidence that 24-hydroxycholesterol,
25-hydroxycholesterol, and 27-hydroxycholesterol are endogenous
agonists of LXRs in the liver (41). We speculate that proteins
involved in the intracellular transport of desmosterol/desmosterol
mimetics restrict their access to SCAP and SREBPs in hepatocytes
but not macrophages. Further understanding of the mechanism
underlying differential actions of desmosterol in macrophages and
hepatocytes thus remains an important future goal.
Materials and Methods
Reagents. Desmosterol was purchased from Avanti Polar Lipids. DMHCA was
resynthesized internally, along with the design and synthesis of MePipHCA.
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Fig. 7. Cell type-specific effects on LXR- and SREBP-responsive genes in vivo.
(A) Gene expression profiling of LXR and SREBP target genes in mouse liver
and peritoneal macrophages (TGEMs) 6 and 16 h after i.p. administration of
T0901317 (T09), DMHCA, and MePipHCA compared with vehicle (M-Pyrol)
(*P < 0.05 vs. Veh). (B) Gene expression profiles of Abca1, Abcg5, and Fasn of
isolated Kupffer cells and whole liver in mice treated with i.p. DMHCA,
T0901317 (T09), or vehicle for 12 h (*P < 0.05 vs. Veh). Error bars represent
standard errors.
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Mevastatin, mevalonolactone, and M-Pyrol were purchased from Sigma-
Aldrich. GW3965 and T0901317 were purchased from Cayman Chemical.
Antisense Oligonucleotides. All antisense oligonucleotides used for these
studies were designed by Ionis Pharmaceuticals to hybridize to the sequence
spanning mouse DHCR24 mRNA. The scrambled control ASO is a chemistry
control ASO that has the same length and chemical make-up as the DHCR24-
specific ASO, and is not expected to hybridize to any mRNA sequence. For in
vitro cell studies, ASOs were transfected into cells using Cytofectin (Genlantis)
at 50 nM final concentration. For animal studies, ASOs were delivered in
sterile saline at either 20 mg ASO per kg animal weight by twice-weekly i.p.
injections or at 100 mg/kg delivered s.c.
Animals. All animal studies were approved by the University of California, San
Diego Institutional Animal Care andUse Committee. Adult male C57BL/6mice
were acquired from Charles River Laboratories. Mice were maintained in an
institutional animal care and use committee-approved animal facility with a
standard light–dark cycle and fed standard laboratory chow.
Thioglycollate-Elicited Macrophage Generation. Peritoneal macrophages were
harvested 4 d after i.p. injection of thioglycollate (refer to Supporting In-
formation for additional details).
Cell Culture. Thioglycollate-elicited macrophages and HepG2 cells were
maintained in RPMI-1640 with 10% FBS and 100 U/mL penicillin/streptomycin
(Cellgro/Corning). Primary mouse hepatocytes were prepared as described
andmaintained in HepatoZYMEmedium (Gibco) with 10% FBS, 1% L-glutamine,
and 1% penicillin/streptomycin (refer to Supporting Information for additional
details).
Isolation and Culture of Human Monocyte-Derived Macrophages. Human
monocyte-derived macrophages were obtained under research protocol
(UCSD IRB-12-0902) approved by the University of California, San Diego In-
stitutional Review Board. Following informed consent, de-identified blood
was obtained from patients undergoing cardiac catheterization from the
arterial sheath after access achieved but prior to any administration of
contrast agent. Human macrophages were prepared from CD14+ peripheral
blood mononuclear cells (PBMCs) isolated from human blood by incubating
in RPMI-1640 + 10% FBS supplemented with penicillin/streptomycin and
50 ng/mL recombinant human macrophage colony-stimulating factor (R&D
Systems) (refer to Supporting Information for additional details).
In Vivo Injection of LXR Agonists and Purification of Kupffer Cells. Mice were
treated by i.p. injection with 50 mg/kg of DMHCA or T0901317 dissolved in
50:50 ethanol and M-Pyrol at a concentration of 50 mg/mL. Twelve hours later,
mice were humanely euthanized by exposure to CO2; whole-liver pieces were
saved and liver nonparenchymal cells were processed for fluorescence-
activated cell sorting of Kupffer cells, with modifications from published
methodology (47, 48) (refer to Supporting Information for additional details).
RNA Isolation and Quantitative PCR. Total RNA was isolated with TRIzol re-
agent (Life Technologies) and Direct-zol RNA spin columns (Zymo Research).
Total RNA was used for either first-strand cDNA synthesis with SuperScript
III (Life Technologies) or RNA-seq library preparation. Real-time PCRs were
prepared in 96-well plates using iTaq SYBR Green Supermix (Bio-Rad) and
performed on the StepOnePlus Quantitative PCR platform (Life Technologies)
(refer to Supporting Information for additional details).
RNA-Sequencing Library Preparation. Please see Supporting Information for
details. Briefly, polyA RNA was used for first-strand cDNA synthesis. Second-
strand synthesis was carried out using deoxy-UTP. Following end repair, the
product was then incubated with EDAC Sera-Mag SpeedBeads (GE Healthcare)
and eluted with manufacturer-supplied elution buffer (Zymo Research). This
was followed by dA tailing, unique barcode adapter ligation, and second-
strand digestion with UDG (Enzymatics). PCR amplification was performed
by 12 to 15 cycles and size-selected for 223 to 375 bp after separating on a
10% Tris borate ethylenediaminetetraacetic acid buffer (TBE) gel (Life Tech-
nologies). The library was purified from the gel slice and single-end–sequenced
on a HiSeq 2000 instrument (Illumina).
Plasma Analysis and Lipid Measurements. Plasma, liver, and TGEMs were
processed at the University of Texas SouthwesternMedical Center for oxysterol
and lipid metabolite analysis by LC-MS as previously described in full (www.
lipidmaps.org/protocols/index.html).
Western Blot Analyses. Protein extracts were fractionated using a 4 to 12% Bis-
Tris NuPAGE (Invitrogen) gel and blotted onto an Immobilon-P PVDF mem-
brane (EMD Millipore). Membranes were incubated with primary antibody
against mouse DHCR24 (Cell Signaling Technology) or beta-actin (Santa Cruz
Biotechnology) overnight at 4 °C followed by a secondary antibody conjugated
to Alexa Fluor 680 (Molecular Probes) or IRDye 800 (Rockland). Membranes
were then imaged using the LI-COR Odyssey. Please see Supporting Informa-
tion for details.
HCS LipidTOX Neutral Lipid Stain Assay. HepG2 cells were plated in 384-well
plates at a density of 5,000 cells per well. The cells were treated with com-
pounds at 1 μM concentration for different time points as indicated, fol-
lowed by fixing with 3% formaldehyde and staining with HCS LipidTOX
neutral lipid stain (H34475; Invitrogen) according to the manufacturer’s
protocol. The lipid content was quantified and analyzed by Cellomics high-
content imaging system and software.
Data Analysis. Experimental values are presented as the means of replicate
experiments ±SE. Aside from the RNA-seq experiments, comparisons among
groups were made using analysis of variance followed by Student’s t test for
pairwise comparison with correction for multiple comparisons. using Prism
7.0 software (GraphPad). Statistical significance was defined as P < 0.05.
Please see Supporting Information for details regarding RNA-seq analysis.
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